| Sign In to gain access to subscriptions and/or personal tools. |
The prognostic value of C-reactive protein in long-term care patients requiring prolonged mechanical ventilationThe Silvercrest Center for Nursing and Rehabilitation, Briarwood, NY, USA; New York Hospital Queens, Flushing, NY, USA vasilismd{at}yahoo.com
The Silvercrest Center for Nursing and Rehabilitation, Briarwood, NY, USA; New York Hospital Queens, Flushing, NY, USA
The Silvercrest Center for Nursing and Rehabilitation, Briarwood, NY, USA
The Silvercrest Center for Nursing and Rehabilitation, Briarwood, NY, USA; New York Hospital Queens, Flushing, NY, USA
C-reactive protein (CRP), a biomarker of inflammation, has predicted mortality in end-stage respiratory failure and in the critically ill patients. Our aim was to investigate if CRP can predict morbidity and mortality in patients requiring prolonged mechanical ventilation. A prospective study conducted in a ventilator weaning unit of a skilled nursing facility over 13 months included 98 patients older than 18 years of age requiring mechanical ventilation via tracheostomy. Serum CRP and albumin levels were tested on admission. Age, gender, body mass index (BMI), and diagnoses causing respiratory failure were recorded. The outcomes measured were as follows: hospitalization, weaned from mechanical ventilation, and death. Our population had a median age of 77 years and the median BMI, albumin, and mean CRP were 26 kg/m2, 2.25 g/dL, and 5.75 mg/dL, respectively. The most common diseases leading to respiratory failure were pulmonary, neurologic, and cardiac. The patients with the empiric cutoff CRP of <2 mg/dL (n = 14) had 0% hospitalization rate at 2 weeks and 7% at 30 days, whereas the patients with CRP
Key Words: chronic respiratory failure C-reactive protein hospitalization mortality prolonged mechanical ventilation
Chronic Respiratory Disease, Vol. 6, No. 3,
149-155 (2009) |
||||
2 mg/dL (n = 84) had 26% hospitalization rate at 2 weeks and 38% at 30 days. Mortality for the patients with CRP
2.7 mg/dL may be used to screen for patients who are not likely to develop acute illness requiring early 2-week rehospitalization, and a CRP level of